|1.||Liu, Jianhua: 1 article (01/2015)|
|2.||Lei, Xiling: 1 article (01/2015)|
|3.||Fraering, Patrick C: 1 article (01/2015)|
|4.||Wu, Fang: 1 article (01/2015)|
|5.||Yu, Jing: 1 article (01/2015)|
|6.||Niu, Qi: 1 article (01/2015)|
|7.||Schneider, L: 1 article (01/2000)|
|8.||Olin, J: 1 article (01/2000)|
|9.||Novit, A: 1 article (01/2000)|
|10.||Luczak, S: 1 article (01/2000)|
01/01/1999 - "It has been described that the association of Dihydroergocristine-Piracetam (D-P) is a useful treatment for vertebro-basilar insufficiency. "
07/01/1984 - "By recording and evaluating these parameters and data patterns, coupled with clinical findings, differential conclusions on reactions of the cerebral hemodynamics in macrocirculatory and microcirculatory regions were realized in geriatric patients under the following pathophysiological and therapeutically induced conditions: Generally and regionally accentuated arteriosclerotic lesions of the brain (predominant vertebrobasilar insufficiency), decrease of flow velocities according to the diameter, aggravation by distress; principal possibility of pharmacological influence if myogenic autoregulation function is rehabilitable: It is demonstrated by the example of a long-term therapy with a combination of Raubasine, Dihydroergocristine and DHE (Defluina forte)."
07/01/1995 - "The only adverse event reported was a case of mild gastric pain at the end of treatment with 20 mg dihydroergocristine."
03/01/2012 - "Dihydroergocristine reversed the antinociception of tianeptine during phase 2, but not during phase 1. Intrathecally administered tianeptine effectively relieved inflammatory pain in rats. "
|3.||Ocular Hypertension (Glaucoma, Suspect)
12/01/1998 - "Our findings suggest that topical dihydroergocristine may be useful in the treatment of ocular hypertension."
12/01/1998 - "The experiments examining the effects of dihydroergocristine on intraocular pressure were conducted in 10 albino rabbits in which ocular hypertension was induced by intracameral injection of alpha-chymotrypsin. "
|4.||Cerebrovascular Disorders (Cerebrovascular Occlusion)
07/16/1982 - "[Trials in the treatment of cerebrovascular insufficiency with the monodrug dihydroergocristine. "
01/01/1990 - "Dihydroergocristine (DHEC) is an ergot derivative used for the therapy of patients with cerebrovascular insufficiency. "
05/01/1982 - "[Controlled clinical trial of dihydroergocristine in neuropsychiatric disorders in cerebrovascular insufficiency]."
|5.||Vascular Diseases (Vascular Disease)
07/01/1995 - "The efficacy and safety of two different regimens of dihydroergocristine, in the treatment of patients with chronic cerebro-vascular disease, were compared in this double-blind study. "
07/01/1995 - "Comparison of the efficacy and safety of daily dosages of 6 mg and 20 mg dihydroergocristine in the treatment of chronic cerebro-vascular disease."
01/01/1971 - "[Study of the association of raubasine and dihydroergocristine in the aged patient with vascular disease]."
|5.||Dihydroergocryptine (Dihydroergocryptine Mesylate)
|6.||Dihydroergotoxine (Hydrogenated Ergot Alkaloids)
|7.||Ergoloid Mesylates (Hydergine)
|10.||methanesulfonic acid (methanesulfonate)